ResearcherHouston MethodistActive in the last 2 years

Alessandro Grattoni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7888-422X; OpenAlex author ID A5030430027. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper

Papers 2

Acoustically Driven Hybrid Nanocrystals for In Vivo Pancreatic Cancer Treatment. Co-author DOI 10.1021/acsami.4c21975 ↗
Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Last author DOI 10.1002/advs.202206873 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Marzia Conte · 1 shared paper, 2025 · strength 0.25
- Paper Acoustically Driven Hybrid Nanocrystals for In Vivo Pancreatic Cancer Treatment. DOI 10.1021/acsami.4c21975 ↗
Marco Carofiglio · 1 shared paper, 2025 · strength 0.25
- Paper Acoustically Driven Hybrid Nanocrystals for In Vivo Pancreatic Cancer Treatment. DOI 10.1021/acsami.4c21975 ↗
Valentina Cauda · 1 shared paper, 2025 · strength 0.25
- Paper Acoustically Driven Hybrid Nanocrystals for In Vivo Pancreatic Cancer Treatment. DOI 10.1021/acsami.4c21975 ↗
Hsuan‐Chen Liu · 1 shared paper, 2023 · strength 0.17
- Paper Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pa… DOI 10.1002/advs.202206873 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.